Pediatric friendly


50% of the people affected by rare diseases are children*


80% of rare diseases have a genetic component*

In 50% of cases, orphan diseases affect children of young age and are responsible for 35% of deaths in the first year of life. Indeed, 80% of orphan diseases have a genetic component and as a result they can arise at any point during a person’s life. *

Because orphan diseases affect people from early childhood to adulthood, Advicenne makes a point of designing and developing medicines in dosage forms that are suitable for both children and adults. This means that Advicenne’s development approach is highly differentiated from other companies working to develop new drugs.

We develop small-size dosage forms of therapeutics, and offer flexible weight-dependent dosing for either children or adults. Weight-dependent dosing increases safety and reduces the risk of over or under dosing.

Our therapeutic dosage forms are tasteless and easy to administer enabling both improved short and long-term therapeutic outcomes as a result of greatly enhanced patient compliance. Advicenne’s dosage forms also aims to improve the treatment experience for both children and adults.

* Neurological Rare Disease « Special Report », February 2015

Children are not just small adults
Many medicinal products are not currently available in formulations suitable for administration to pediatric population. Consequently, crushing tablets or opening capsules to administer a smaller dose is a common practice.
The manipulation of adult dosage forms for children is at high risk of over or under-dosing, with as consequences issues of efficacy, tolerance, safety and compliance.

Adequate pharmaceutical forms associated with the availability of high-quality clinical data in children are required to provide better and suitable pediatric medication, to improve treatment compliance and children’s quality of life.